1. Home
  2. WMS vs TGTX Comparison

WMS vs TGTX Comparison

Compare WMS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Advanced Drainage Systems Inc.

WMS

Advanced Drainage Systems Inc.

HOLD

Current Price

$139.08

Market Cap

10.3B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$51.99

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WMS
TGTX
Founded
1966
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
8.5B
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
WMS
TGTX
Price
$139.08
$51.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$180.63
$49.80
AVG Volume (30 Days)
537.9K
2.0M
Earning Date
05-21-2026
05-04-2026
Dividend Yield
0.49%
N/A
EPS Growth
N/A
1746.67
EPS
5.44
0.12
Revenue
$3,050,376,000.00
$2,785,000.00
Revenue This Year
$5.23
$49.08
Revenue Next Year
$12.79
$26.69
P/E Ratio
$25.37
$447.08
Revenue Growth
5.03
N/A
52 Week Low
$112.67
$25.37
52 Week High
$179.32
$59.30

Technical Indicators

Market Signals
Indicator
WMS
TGTX
Relative Strength Index (RSI) 42.91 45.12
Support Level $130.46 $51.22
Resistance Level $154.50 $58.34
Average True Range (ATR) 4.09 2.16
MACD -1.12 -0.72
Stochastic Oscillator 15.05 12.55

Price Performance

Historical Comparison
WMS
TGTX

About WMS Advanced Drainage Systems Inc.

Advanced Drainage Systems Inc designs, manufactures and markets water management solutions in the stormwater and onsite wastewater industries, providing superior drainage solutions for use in the construction and agriculture markets. The company's products are used across a broad range of end markets and applications, including non-residential, residential, infrastructure and agriculture applications. It has two reportable segments: Stormwater and Wastewater. It derives the majority of revenue from the Stormwater segment, which manufactures and markets thermoplastic corrugated pipe and complementary products, including single wall pipe, N-12 HDPE pipe, polypropylene pipe, StormTech, Nyloplast, Inserta Tee, water quality filters and structures, and NDS channel drains, and access boxes.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: